Federal Register
Notice: FDA has determined the regulatory review period for Santen Pharmaceutical Co.’s Alamast (pemirolast potassium) is 1,298 days for extending a patent that claims the human drug product. Alamast is indicated for preventing itching of the eye due to allergic conjunctivitis. To view this notice, click here.